Otsuka’s Samsca Wins Add’l Indication for Fluid Retention in Liver Cirrhosis Patients; World’s 1st Such Approval

Otsuka Pharmaceutical announced on September 17 that the Ministry of Health, Labor and Welfare has granted the aquaretic agent Samsca 7.5 mg Tablets (tolvaptan) an additional indication for the treatment of fluid retention in patients with liver cirrhosis. The drug...read more